Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
NovaRx Corporation
ClinicalTrials.gov Identifier:
NCT00676507
First received: May 8, 2008
Last updated: May 29, 2012
Last verified: May 2012